Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Mydayis

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 3 (1)
Phase 4 (1)

Trial Status

Completed2
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT03945175Phase 3CompletedPrimary

Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening

NCT00205699Phase 4Completed

Metabolic Effects of Antipsychotics in Children

NCT03546010Not ApplicableUnknownPrimary

Oculometry as an Attentional Mechanism Evaluation Tool and Attention Deficit Hyperactivity Inhibition

Showing all 3 trials

Research Network

Common Treatments

  • Mydayis1
  • Aripiprazole1
  • Neuropsychological Tests1
  • Oculometric Tests1
  • Risperidone1

Active Sponsors

  • University Hospital, Grenoble1
  • NYU Langone Health1
  • Washington University School of Medicine1
  • National Institute of Mental Health (NIMH)1

Top Investigators

Related Conditions

  • Oppositional Defiant Disorder1
  • Pervasive Development Disorders1
  • Bipolar Disorder1
  • Aggression1

Activity Timeline